• Company
• Leading companies in developing new PO microbiome drugs
• by Nho, Byung Chul May 24, 2023 08:28pm

• Policy
• Domestic medical device market share ↑50%
• by Lee, Hye-Kyung May 24, 2023 08:26pm

• Company
• Pharma industry on alert over business risks in China
• by Lee, Seok-Jun May 24, 2023 05:32am

• Product
• The expansion of OTC medicine at convenience stores
• by Kim JiEun May 24, 2023 05:32am

• Company
• Leclaza posts sales of KRW 25 bil in 2 years in Korea
• by Chon, Seung-Hyun May 24, 2023 05:32am

• Company
• Merck retrieves rights to PD-L1 antibody Bavencio in Korea
• by Eo, Yun-Ho May 23, 2023 05:54am

• Company
• RWD results reaffirm Leclaza’s efficacy in practice
• by Chon, Seung-Hyun May 23, 2023 05:54am

• InterView
• The use of HTN combi tx in Korea is the highest in the world
• by May 23, 2023 05:53am

• Policy
• Domestic DM combi drugs selected for market competitiveness
• by Lee, Tak-Sun May 23, 2023 05:50am

• Company
• SGLT2 lowers BP, but more evidence is needed to use it alone
• by Hwang, Jin-joon May 23, 2023 05:50am